^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | CI-1040 (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
Excerpt:
The findings in this study indicate that an activated ERK1/2 pathway is critical to tumour growth and survival of ovarian cancers with KRAS or BRAF mutations. Furthermore, they suggest that the CI-1040-induced phenotypes depend on the mutational status of KRAS and BRAF in ovarian cancers. Therefore, ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment.
DOI:
10.1038/sj.bjc.6604783
